MovDisordV3, PascalFrancis, Corpus, bibRecord, 000B43

Hyposmia in Progressive Supranuclear Palsy

Identifieur interne : 000B43 ( PascalFrancis/Corpus ); précédent : 000B42; suivant : 000B44

Hyposmia in Progressive Supranuclear Palsy

Auteurs : Laura Silveira-Moriyama ; Graham Hughes ; Alistair Church ; Hilary Ayling ; David R. Williams ; Aviva Petrie ; Janice Holton ; Tamas Revesz ; Ann Kingsbury ; Huw R. Morris ; David J. Burn ; Andrew J. Lees

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0233212

Descripteurs français

Pascal (Inist)
- Trouble de l'odorat, Maladie de Parkinson, Pathologie du système nerveux, Ophtalmoplégie supranucléaire, Postmortem, Olfaction.

English descriptors

KwdEn :
- Nervous system diseases, Olfaction, Olfactory disorder, Parkinson disease, Postmortem, Supranuclear ophthalmoplegia.

Abstract

Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Hyposmia in Progressive Supranuclear Palsy`
A11	`01`	`1`		`@1 SILVEIRA-MORIYAMA (Laura)`
A11	`02`	`1`		`@1 HUGHES (Graham)`
A11	`03`	`1`		`@1 CHURCH (Alistair)`
A11	`04`	`1`		`@1 AYLING (Hilary)`
A11	`05`	`1`		`@1 WILLIAMS (David R.)`
A11	`06`	`1`		`@1 PETRIE (Aviva)`
A11	`07`	`1`		`@1 HOLTON (Janice)`
A11	`08`	`1`		`@1 REVESZ (Tamas)`
A11	`09`	`1`		`@1 KINGSBURY (Ann)`
A11	`10`	`1`		`@1 MORRIS (Huw R.)`
A11	`11`	`1`		`@1 BURN (David J.)`
A11	`12`	`1`		`@1 LEES (Andrew J.)`
A14	`01`			`@1 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology @2 London @3 GBR @Z 1 aut. @Z 5 aut. @Z 7 aut. @Z 9 aut. @Z 12 aut.`
A14	`02`			`@1 Institute for Ageing and Health, Newcastle University @2 Newcastle Upon Tyne @3 GBR @Z 2 aut. @Z 11 aut.`
A14	`03`			`@1 Department of Neurology, Royal Gwent Hospital, Newport @2 Gwent @3 GBR @Z 3 aut.`
A14	`04`			`@1 Queen Square Brain Bank, UCL Institute of Neurology @2 London @3 GBR @Z 4 aut. @Z 7 aut. @Z 8 aut. @Z 12 aut.`
A14	`05`			`@1 Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus) @2 Melbourne @3 AUS @Z 5 aut.`
A14	`06`			`@1 Biostatistics Unit, UCL Eastman Dental Institute @2 London @3 GBR @Z 6 aut.`
A14	`07`			`@1 Department of Neurology, Cardiff University School of Medicine, Cardiff University @2 Cardiff @3 GBR @Z 10 aut.`
A20				`@1 570-577`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000181079390080`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 10-0233212`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Trouble de l'odorat @5 01`
C03	`01`	`X`	`ENG`	`@0 Olfactory disorder @5 01`
C03	`01`	`X`	`SPA`	`@0 Trastorno olfatorio @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Ophtalmoplégie supranucléaire @5 09`
C03	`04`	`X`	`ENG`	`@0 Supranuclear ophthalmoplegia @5 09`
C03	`04`	`X`	`SPA`	`@0 Oftalmoplejía supranuclear @5 09`
C03	`05`	`X`	`FRE`	`@0 Postmortem @5 10`
C03	`05`	`X`	`ENG`	`@0 Postmortem @5 10`
C03	`05`	`X`	`SPA`	`@0 Postmortem @5 10`
C03	`06`	`X`	`FRE`	`@0 Olfaction @5 11`
C03	`06`	`X`	`ENG`	`@0 Olfaction @5 11`
C03	`06`	`X`	`SPA`	`@0 Olfación @5 11`
C07	`01`	`X`	`FRE`	`@0 Trouble neurologique @5 38`
C07	`01`	`X`	`ENG`	`@0 Neurological disorder @5 38`
C07	`01`	`X`	`SPA`	`@0 Trastorno neurológico @5 38`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`02`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`02`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 40`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 40`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 40`
C07	`04`	`X`	`FRE`	`@0 Syndrome oculomoteur @5 41`
C07	`04`	`X`	`ENG`	`@0 Oculomotor syndrome @5 41`
C07	`04`	`X`	`SPA`	`@0 Oculomotricidad síndrome @5 41`
C07	`05`	`X`	`FRE`	`@0 Pathologie de l'oeil @5 42`
C07	`05`	`X`	`ENG`	`@0 Eye disease @5 42`
C07	`05`	`X`	`SPA`	`@0 Ojo patología @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
C07	`07`	`X`	`FRE`	`@0 Syndrome du tronc cérébral @5 44`
C07	`07`	`X`	`ENG`	`@0 Brain stem syndrome @5 44`
C07	`07`	`X`	`SPA`	`@0 Tallo encefalico sindrome @5 44`
C07	`08`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 45`
C07	`08`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 45`
C07	`08`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 45`
N21				`@1 158`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0233212 INIST
ET :	Hyposmia in Progressive Supranuclear Palsy
AU :	SILVEIRA-MORIYAMA (Laura); HUGHES (Graham); CHURCH (Alistair); AYLING (Hilary); WILLIAMS (David R.); PETRIE (Aviva); HOLTON (Janice); REVESZ (Tamas); KINGSBURY (Ann); MORRIS (Huw R.); BURN (David J.); LEES (Andrew J.)
AF :	Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology/London/Royaume-Uni (1 aut., 5 aut., 7 aut., 9 aut., 12 aut.); Institute for Ageing and Health, Newcastle University/Newcastle Upon Tyne/Royaume-Uni (2 aut., 11 aut.); Department of Neurology, Royal Gwent Hospital, Newport/Gwent/Royaume-Uni (3 aut.); Queen Square Brain Bank, UCL Institute of Neurology/London/Royaume-Uni (4 aut., 7 aut., 8 aut., 12 aut.); Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus)/Melbourne/Australie (5 aut.); Biostatistics Unit, UCL Eastman Dental Institute/London/Royaume-Uni (6 aut.); Department of Neurology, Cardiff University School of Medicine, Cardiff University/Cardiff/Royaume-Uni (10 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 5; Pp. 570-577; Bibl. 41 ref.
LA :	Anglais
EA :	Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.
CC :	002B17; 002B17G
FD :	Trouble de l'odorat; Maladie de Parkinson; Pathologie du système nerveux; Ophtalmoplégie supranucléaire; Postmortem; Olfaction
FG :	Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du système nerveux central; Syndrome du tronc cérébral; Syndrome extrapyramidal
ED :	Olfactory disorder; Parkinson disease; Nervous system diseases; Supranuclear ophthalmoplegia; Postmortem; Olfaction
EG :	Neurological disorder; Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome; Extrapyramidal syndrome
SD :	Trastorno olfatorio; Parkinson enfermedad; Sistema nervioso patología; Oftalmoplejía supranuclear; Postmortem; Olfación
LO :	INIST-20953.354000181079390080
ID :	10-0233212

Links to Exploration step

Pascal:10-0233212

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Hyposmia in Progressive Supranuclear Palsy</title>
<author><name sortKey="Silveira Moriyama, Laura" sort="Silveira Moriyama, Laura" uniqKey="Silveira Moriyama L" first="Laura" last="Silveira-Moriyama">Laura Silveira-Moriyama</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hughes, Graham" sort="Hughes, Graham" uniqKey="Hughes G" first="Graham" last="Hughes">Graham Hughes</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Church, Alistair" sort="Church, Alistair" uniqKey="Church A" first="Alistair" last="Church">Alistair Church</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Royal Gwent Hospital, Newport</s1>
<s2>Gwent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ayling, Hilary" sort="Ayling, Hilary" uniqKey="Ayling H" first="Hilary" last="Ayling">Hilary Ayling</name>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, David R" sort="Williams, David R" uniqKey="Williams D" first="David R." last="Williams">David R. Williams</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus)</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Petrie, Aviva" sort="Petrie, Aviva" uniqKey="Petrie A" first="Aviva" last="Petrie">Aviva Petrie</name>
<affiliation><inist:fA14 i1="06"><s1>Biostatistics Unit, UCL Eastman Dental Institute</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holton, Janice" sort="Holton, Janice" uniqKey="Holton J" first="Janice" last="Holton">Janice Holton</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Revesz, Tamas" sort="Revesz, Tamas" uniqKey="Revesz T" first="Tamas" last="Revesz">Tamas Revesz</name>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kingsbury, Ann" sort="Kingsbury, Ann" uniqKey="Kingsbury A" first="Ann" last="Kingsbury">Ann Kingsbury</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Huw R" sort="Morris, Huw R" uniqKey="Morris H" first="Huw R." last="Morris">Huw R. Morris</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Cardiff University School of Medicine, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0233212</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0233212 INIST</idno>
<idno type="RBID">Pascal:10-0233212</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Hyposmia in Progressive Supranuclear Palsy</title>
<author><name sortKey="Silveira Moriyama, Laura" sort="Silveira Moriyama, Laura" uniqKey="Silveira Moriyama L" first="Laura" last="Silveira-Moriyama">Laura Silveira-Moriyama</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hughes, Graham" sort="Hughes, Graham" uniqKey="Hughes G" first="Graham" last="Hughes">Graham Hughes</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Church, Alistair" sort="Church, Alistair" uniqKey="Church A" first="Alistair" last="Church">Alistair Church</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Royal Gwent Hospital, Newport</s1>
<s2>Gwent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ayling, Hilary" sort="Ayling, Hilary" uniqKey="Ayling H" first="Hilary" last="Ayling">Hilary Ayling</name>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Williams, David R" sort="Williams, David R" uniqKey="Williams D" first="David R." last="Williams">David R. Williams</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus)</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Petrie, Aviva" sort="Petrie, Aviva" uniqKey="Petrie A" first="Aviva" last="Petrie">Aviva Petrie</name>
<affiliation><inist:fA14 i1="06"><s1>Biostatistics Unit, UCL Eastman Dental Institute</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holton, Janice" sort="Holton, Janice" uniqKey="Holton J" first="Janice" last="Holton">Janice Holton</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Revesz, Tamas" sort="Revesz, Tamas" uniqKey="Revesz T" first="Tamas" last="Revesz">Tamas Revesz</name>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kingsbury, Ann" sort="Kingsbury, Ann" uniqKey="Kingsbury A" first="Ann" last="Kingsbury">Ann Kingsbury</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morris, Huw R" sort="Morris, Huw R" uniqKey="Morris H" first="Huw R." last="Morris">Huw R. Morris</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Cardiff University School of Medicine, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J." last="Burn">David J. Burn</name>
<affiliation><inist:fA14 i1="02"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lees, Andrew J" sort="Lees, Andrew J" uniqKey="Lees A" first="Andrew J." last="Lees">Andrew J. Lees</name>
<affiliation><inist:fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Olfaction</term>
<term>Olfactory disorder</term>
<term>Parkinson disease</term>
<term>Postmortem</term>
<term>Supranuclear ophthalmoplegia</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Trouble de l'odorat</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Ophtalmoplégie supranucléaire</term>
<term>Postmortem</term>
<term>Olfaction</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Hyposmia in Progressive Supranuclear Palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SILVEIRA-MORIYAMA (Laura)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HUGHES (Graham)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHURCH (Alistair)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>AYLING (Hilary)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WILLIAMS (David R.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PETRIE (Aviva)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HOLTON (Janice)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>REVESZ (Tamas)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KINGSBURY (Ann)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MORRIS (Huw R.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>BURN (David J.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>LEES (Andrew J.)</s1>
</fA11>
<fA14 i1="01"><s1>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute for Ageing and Health, Newcastle University</s1>
<s2>Newcastle Upon Tyne</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Royal Gwent Hospital, Newport</s1>
<s2>Gwent</s2>
<s3>GBR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Queen Square Brain Bank, UCL Institute of Neurology</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus)</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Biostatistics Unit, UCL Eastman Dental Institute</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Cardiff University School of Medicine, Cardiff University</s1>
<s2>Cardiff</s2>
<s3>GBR</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>570-577</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000181079390080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0233212</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Trouble de l'odorat</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Olfactory disorder</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Trastorno olfatorio</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Ophtalmoplégie supranucléaire</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Supranuclear ophthalmoplegia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Oftalmoplejía supranuclear</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Postmortem</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Postmortem</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Postmortem</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Olfaction</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Olfaction</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Olfación</s0>
<s5>11</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>38</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Syndrome oculomoteur</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Oculomotor syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Oculomotricidad síndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'oeil</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Syndrome du tronc cérébral</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Brain stem syndrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Tallo encefalico sindrome</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>45</s5>
</fC07>
<fN21><s1>158</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0233212 INIST</NO>
<ET>Hyposmia in Progressive Supranuclear Palsy</ET>
<AU>SILVEIRA-MORIYAMA (Laura); HUGHES (Graham); CHURCH (Alistair); AYLING (Hilary); WILLIAMS (David R.); PETRIE (Aviva); HOLTON (Janice); REVESZ (Tamas); KINGSBURY (Ann); MORRIS (Huw R.); BURN (David J.); LEES (Andrew J.)</AU>
<AF>Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology/London/Royaume-Uni (1 aut., 5 aut., 7 aut., 9 aut., 12 aut.); Institute for Ageing and Health, Newcastle University/Newcastle Upon Tyne/Royaume-Uni (2 aut., 11 aut.); Department of Neurology, Royal Gwent Hospital, Newport/Gwent/Royaume-Uni (3 aut.); Queen Square Brain Bank, UCL Institute of Neurology/London/Royaume-Uni (4 aut., 7 aut., 8 aut., 12 aut.); Department of Neurology, Faculty of Medicine (Neurosciences), Monash University (Alfred Hospital Campus)/Melbourne/Australie (5 aut.); Biostatistics Unit, UCL Eastman Dental Institute/London/Royaume-Uni (6 aut.); Department of Neurology, Cardiff University School of Medicine, Cardiff University/Cardiff/Royaume-Uni (10 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 5; Pp. 570-577; Bibl. 41 ref.</SO>
<LA>Anglais</LA>
<EA>Previous studies suggested that olfaction is normal in progressive supranuclear palsy (PSP). We applied the University of Pennsylvania Smell Identification Test (UPSIT) to 36 patients with PSP who scored more than 18 on the Mini Mental State Examination (MMSE), 140 patients with nondemented Parkinson's disease (PD) and 126 controls. Mean UPSIT scores in PSP were lower than in controls (P < 0.001) but higher than in PD (P < 0.001) after adjusting for age, gender, and smoking history. For patients with PSP, UPSIT scores correlated with MMSE (r = 0.44, P = 0.006) but not disease duration (P = 0.6), motor subscale of the Unified Parkinson's Disease Rating Scale (P = 0.2), or Frontal Assessment Battery (P = 0.5). The brains of six of the patients with PSP were examined postmortem and all revealed neurofibrillary tangles and tau accumulation in the rhinencephalon, although only three had hyposmia. Further prospective studies including patients with early PSP and PSP-P with postmortem confirmation might help clarify if smell tests could be useful when the differential diagnosis lies between PD and PSP.</EA>
<CC>002B17; 002B17G</CC>
<FD>Trouble de l'odorat; Maladie de Parkinson; Pathologie du système nerveux; Ophtalmoplégie supranucléaire; Postmortem; Olfaction</FD>
<FG>Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Syndrome oculomoteur; Pathologie de l'oeil; Pathologie du   système nerveux central; Syndrome du tronc cérébral; Syndrome extrapyramidal</FG>
<ED>Olfactory disorder; Parkinson disease; Nervous system diseases; Supranuclear ophthalmoplegia; Postmortem; Olfaction</ED>
<EG>Neurological disorder; Cerebral disorder; Degenerative disease; Oculomotor syndrome; Eye disease; Central nervous system disease; Brain stem syndrome; Extrapyramidal syndrome</EG>
<SD>Trastorno olfatorio; Parkinson enfermedad; Sistema nervioso patología; Oftalmoplejía supranuclear; Postmortem; Olfación</SD>
<LO>INIST-20953.354000181079390080</LO>
<ID>10-0233212</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B43 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B43 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0233212
   |texte=   Hyposmia in Progressive Supranuclear Palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Hyposmia in Progressive Supranuclear Palsy

Hyposmia in Progressive Supranuclear Palsy

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri